416 related articles for article (PubMed ID: 24479980)
1. Review article: anti-adhesion therapies for inflammatory bowel disease.
Lobatón T; Vermeire S; Van Assche G; Rutgeerts P
Aliment Pharmacol Ther; 2014 Mar; 39(6):579-94. PubMed ID: 24479980
[TBL] [Abstract][Full Text] [Related]
2. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.
Thomas S; Baumgart DC
Inflammopharmacology; 2012 Feb; 20(1):1-18. PubMed ID: 22205271
[TBL] [Abstract][Full Text] [Related]
3. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
4. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
[TBL] [Abstract][Full Text] [Related]
5. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
[TBL] [Abstract][Full Text] [Related]
6. Baseline levels of dynamic CD4
Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation Therapeutics for IBD.
Löwenberg M; D'Haens G
Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.
Ghosh N; Chaki R; Mandal SC
Int Rev Immunol; 2012 Oct; 31(5):410-27. PubMed ID: 23083349
[TBL] [Abstract][Full Text] [Related]
9. Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s.
Binder MT; Becker E; Wiendl M; Schleier L; Fuchs F; Leppkes M; Atreya R; Neufert C; Atreya I; Neurath MF; Zundler S
Inflamm Bowel Dis; 2018 May; 24(6):1237-1250. PubMed ID: 29788362
[TBL] [Abstract][Full Text] [Related]
10. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
Lamb CA; O'Byrne S; Keir ME; Butcher EC
J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
[TBL] [Abstract][Full Text] [Related]
11. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
13. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.
Sugiura T; Kageyama S; Andou A; Miyazawa T; Ejima C; Nakayama A; Dohi T; Eda H
J Crohns Colitis; 2013 Dec; 7(11):e533-42. PubMed ID: 23623333
[TBL] [Abstract][Full Text] [Related]
14. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
[TBL] [Abstract][Full Text] [Related]
15. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
16. Biological therapies for inflammatory bowel disease: research drives clinics.
Danese S; Semeraro S; Armuzzi A; Papa A; Gasbarrini A
Mini Rev Med Chem; 2006 Jul; 6(7):771-84. PubMed ID: 16842127
[TBL] [Abstract][Full Text] [Related]
17. Integrins and adhesion molecules as targets to treat inflammatory bowel disease.
Bravatà I; Allocca M; Fiorino G; Danese S
Curr Opin Pharmacol; 2015 Dec; 25():67-71. PubMed ID: 26687159
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.
Catalan-Serra I; Brenna Ø
Hum Vaccin Immunother; 2018; 14(11):2597-2611. PubMed ID: 29624476
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
Jovani M; Danese S
Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
[TBL] [Abstract][Full Text] [Related]
20. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]